# Beijing Zhiyin Biomedical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-zhiyin-biomedical-technology-co

- Headquarters: Beijing, China
- Latest round: Seed (Sep 22, 2026)
- Investors on record: 1

## About

Based in Beijing, China and founded in 2026, Beijing Zhiyin Biomed Technology Co., Ltd. is an innovative biopharmaceutical company specializing in AI-powered cell reprogramming technologies. In September 2026, it raised tens of millions of CNY in Seed funding led by Shanxi Growth Enterprise Leading Fund.

Beijing Zhiyin Biomedical Technology Co., Ltd. develops the proprietary iCellFate Cell Fate Programming Operating System, an integrated technology platform combining chemical reprogramming (CPiCR), RNA reprogramming (RNAiCR), and dCas9-based in vivo reprogramming (CRISPRiCR). These technologies enable the reprogramming of cell identity and cellular states through epigenetic regulation without modifying DNA sequences. The company leverages artificial intelligence, high-throughput screening, molecular design technologies, and multi-omics data analysis to develop novel therapeutic candidates.

The company generates revenue through the development and commercialization of cell therapy products, regenerative medicine therapies, technology licensing, and research collaborations.

The company will use the Seed funding to support its preclinical research on core pipelines, IND filings, and the construction and equipment procurement for GMP laboratories, thereby accelerating the clinical translation of cell reprogramming technology.

## Funding rounds

- Seed, Sep 22, 2026 — Shanxi Growth Enterprise Leading Fund

## Investors

- Shanxi Growth Enterprise Leading Fund (https://capitalatlas.ai/funds/shanxi-growth-enterprise-leading-fund) — Seed